NCT06369623 Monetary Incentive Delay Task for Probing Reward-related Neural Processes
| NCT ID | NCT06369623 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stony Brook University |
| Condition | Adolescent Development |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-04-06 |
| Primary Completion | 2028-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-04-06 with a primary completion date of 2028-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
150 males and 150 females ages 14-17 years-old will be enrolled in an observational, longitudinal study. There are three planned in-person visits: a baseline assessment, an 18-month follow-up, and a 36-month follow-up. The in-person visits will include assessment of substance use and other individual differences (e.g., reward function, psychiatric history), neuromelanin-sensitive MRI, as well as functional brain activation collected while the participant is at rest (resting-state fMRI) and while the participant completes a Monetary Incentive Delay task. Subjects will also be asked to complete past 90-day substance use assessments remotely every 90 days for 36 months.
Eligibility Criteria
Inclusion Criteria: * Males and females ages 14-17 years-old; * English-speaking for assent and interview completion; * Capacity to provide assent. * For parents, the inclusion criteria will be willing and capacity to provide parental permission/consent. Exclusion Criteria: * current (within 6 months) use of medication that may affect cerebral function * history of severe medical or neurological illness, including stroke or seizure; * history of head trauma with loss of consciousness; * presence of metal in the body; * pregnancy or breastfeeding; * recent drug or alcohol use determined by positive urine toxicology or breathalyzer (to validate self-report assessment of substance use history); * lifetime use of psychotropic or other medication that could likely influence dopamine function, namely stimulant medication or antipsychotic medication, except a subgroup of 25 youth with history of prescribed stimulant medication and a subgroup of 15 youth with history antipsychotic medication will be enrolled for comparison purposes.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06369623 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 17 Years, studying Adolescent Development. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06369623 currently recruiting?
Yes, NCT06369623 is actively recruiting participants. Contact the research team at greg.perlman@stonybrookmedicine.edu for enrollment information.
Where is the NCT06369623 trial being conducted?
This trial is being conducted at Stony Brook, United States.
Who is sponsoring the NCT06369623 clinical trial?
NCT06369623 is sponsored by Stony Brook University. The trial plans to enroll 300 participants.